Abstracts
Purpose
This study aims to determine the numbers of patients with advanced cancer receiving polypharmacy at the end of their lives and analyze differences in drug prescription at a general oncology ward and a dedicated palliative care ward.
Methods
A retrospective single-center cohort study at a university hospital with a large cancer center was conducted. The charts of 100 patients who had died because of advanced cancer were reviewed; data concerning sociodemographic variables and medications were collected at four predefined time points (9, 6, 3, 0 days before death).
Results
Nine days before death, polypharmacy was registered in 95 % of patients; they had prescriptions for 11 (9–13) different medications per day (median, IQR). Although this number dropped significantly, on the last day as many as 61 % of the patients were still taking more than 4 drugs (median 6.5, IQR 4–9). No significant difference was noted between the oncology ward and the palliative care ward. Polypharmacy was largely dependent on the patients’ ECOG performance status as well as the type of ward, the number of days before death, and age. It was not influenced by gender, the duration of hospital stays, and the devices facilitating drug administration. The medications fulfilled the requirements of palliative care in the majority of patients; 90 % received treatment for pain and anxiety. Patients treated at the palliative ward received more opioids and psychoactive drugs while those at the oncology ward received more anti-cancer drugs and fluids.
Conclusions
Polypharmacy still is a problem in the large majority of patients with terminal cancer. Further studies should be focused on the patients’ quality of life, drug interactions, and adverse events.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kaufman DW, Kelly JP, Rosenberg L et al (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344
Merlis S, Sheppard C, Collins L, Fiorentino D (1970) Polypharmacy in psychiatry: patterns of differential treatment. Am J Psychiatry 126:1647–1651
Cullen SC (1957) Polypharmacy in anesthesia. Surg Gynecol Obstet 104:113–114
Grant-Whyte H (1961) Irrational polypharmacy in anaesthesia. S Afr Med J 35:1016–1021
(1966) Patients and polypharmacy. Can Med Assoc J 94:456.
Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261–267
Gnjidic D, Hilmer SN, Blyth FM et al (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65:989–995. doi:10.1016/j.jclinepi.2012.02.018
Jyrkkä J, Vartiainen L, Hartikainen S et al (2006) Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study. Eur J Clin Pharmacol 62:151–158. doi:10.1007/s00228-005-0079-6
Bushardt RL, Massey EB, Simpson TW et al (2008) Polypharmacy: misleading, but manageable. Clin Interv Aging 3:383–389
Jyrkkä J, Enlund H, Lavikainen P et al (2011) Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 20:514–522. doi:10.1002/pds.2116
Hajjar ER, Hanlon JT, Sloane RJ et al (2005) Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc 53:1518–1523. doi:10.1111/j.1532-5415.2005.53523.x
Maggiore RJ, Gross CP, Hurria A (2010) Polypharmacy in older adults with cancer. Oncologist 15:507–522. doi:10.1634/theoncologist.2009-0290
LeBlanc TW, McNeil MJ, Kamal AH et al (2015) Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 16:e333–e341. doi:10.1016/S1470-2045(15)00080-7
Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:447–450. doi:10.1016/S0735-6757(96)90147-3
Tamura BK, Bell CL, Inaba M, Masaki KH (2012) Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med 28:217–236. doi:10.1016/j.cger.2012.01.005
Popa MA, Wallace KJ, Brunello A et al (2014) Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol 5:307–314. doi:10.1016/j.jgo.2014.04.002
Van Leeuwen RWF, Swart EL, Boom FA et al (2010) Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer 10:679. doi:10.1186/1471-2407-10-679
Garfinkel D, Zur-Gil S, Ben-Israel J (2007) The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 9:430–434
Lees J, Chan A (2011) Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 12:1249–1257. doi:10.1016/S1470-2045(11)70040-7
Riechelmann RP, Krzyzanowska MK, O’Carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15:1407–1412. doi:10.1007/s00520-007-0253-8
Frechen S, Zoeller A, Ruberg K et al (2012) Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf 35:745–758. doi:10.2165/11631280-000000000-00000
Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107
Lundy E, McMullan D, McShane P et al (2013) Polypharmacy and drug omissions across hospices in Northern Ireland. J Palliat Med 16:1446–1449. doi:10.1089/jpm.2013.0090
McLean S, Sheehy-Skeffington B, O’Leary N, O’Gorman A (2013) Pharmacological management of co-morbid conditions at the end of life: is less more? Ir J Med Sci 182:107–112. doi:10.1007/s11845-012-0841-6
Sera L, McPherson ML, Holmes HM (2014) Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care 31:126–131. doi:10.1177/1049909113476132
Currow DC, Stevenson JP, Abernethy AP et al (2007) Prescribing in palliative care as death approaches. J Am Geriatr Soc 55:590–595. doi:10.1111/j.1532-5415.2007.01124.x
Acknowledgments
We gratefully acknowledge the dedicated work and cooperation of the staff at the oncology and palliative care wards of the Department of Medicine I, Medical University of Vienna.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
None
Rights and permissions
About this article
Cite this article
Kierner, K.A., Weixler, D., Masel, E.K. et al. Polypharmacy in the terminal stage of cancer. Support Care Cancer 24, 2067–2074 (2016). https://doi.org/10.1007/s00520-015-3007-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-015-3007-z